RZLT logo

REZOLUTE INC

RZLTNASDAQ
🏆 #3134 by market capUS Equity
$711.79▲ $51.68 (+7.26%)
Simulated price
🔔
Track RZLT
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 7.3%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$403M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
72
Fair
No chart data available for RZLT.

Trading Snapshot

Day Range
$702.59 – $722.41
52-Week Range
$1.07 – $11.46
Volume
$3.31B
Avg Volume
$4.01B
Shares Outstanding
96.3M
Next Earnings
Nov 15, 2026

Fundamentals Snapshot

Annual Revenue
$77M
Last Q Revenue
$19M
P/E Ratio
-5.5
P/S Ratio
0.0x
EPS (TTM)
$-0.74
Dividend Yield
0.00%
Dilution (1yr)
+0.8%

Why Investors Own RZLT

  • ✓High-growth profile — revenue up +58.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 36% gross margin and 19% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

RZLT logo

REZOLUTE INC

RZLT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$83M▲ +3.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$65M▼ −6.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
104.5M▲ +0.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$10M▼ −$978K YoY
StockOtter · stockotter.space

About REZOLUTE INC

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$882.08
▲ +23.9% Upside
High Target$1,060.23
Low Target$789.03
Based on 16 analysts

Latest News & Updates

🚀
Reuters·2h ago

REZOLUTE INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift RZLT price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

REZOLUTE INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.